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Introduction
The stem cell niche is a key characteristic of germative epithelia. 
Renewal of nongermative epithelia is by defi  nition much more 
challenging to address. Yet, nongermative epithelia comprise 
most adult organs of the body, including exocrine and endo-
crine glands, kidney, and liver (Rizvi and Wong, 2005). Recent 
cell lineage studies in the adult endocrine pancreas suggested 
that differentiated β-cells are renewed by self-duplication rather 
than via stem cells (Dor et al., 2004). General applicability to 
other nongermative epithelia has not been explored. However, 
this observation is in keeping with early [
3H]TdR incorporation 
studies of exocrine and endocrine pancreas, liver, trachea, kid-
ney, and the salivary, thyroid, and adrenal glands (Messier and 
Leblond, 1960). A dynamically regulated state of differentiation 
is suggested by successful nuclear transfer from differentiated 
donor cells, and by the fusibility of differentiated muscle and 
brain cells with bone marrow stem cells (Sacco et al., 2005). 
If nongermative epithelia are broadly proliferative, one im-
plication is that mitogenic stimuli are correspondingly widely 
dispersed—much like the luminal distribution of differentiative 
hedgehog along the intestinal villus axis.
The human mitogen lacritin is preferentially associated 
with nongermative epithelia. Lacritin is apically secreted by 
acinar cells in the adult lacrimal gland and by a subpopulation 
of ductal cells in salivary glands (Sanghi et al., 2001), and it has 
been detected by nonhistological methods in thyroid (Sanghi 
et al., 2001) and mammary glands (Weigelt et al., 2003) and 
some ocular surface cells, but not elsewhere. Acinar lumina 
and long ducts transport lacritin past apical membranes of the 
nongermative epithelia comprising both glands. Later, lacritin 
is deposited onto the rapidly renewing epithelia on the surface 
of the eye and mouth, where it can be detected by ELISA. Thus, 
instead of localized release to nurture crypt stem cells, as per 
Wnts, lacritin is apically secreted for broad distribution.  Lacritin 
may therefore stimulate epithelia in its downstream path. 
Supporting this hypothesis are in vitro studies showing recom-
binant lacritin to be capable of promoting lacrimal acinar cell 
secretion, human salivary ductal cell proliferation, and Ca
2+ 
mobilization by human corneal epithelial (HCE) cells (Sanghi 
et al., 2001). Thus, release of lacritin may hypothetically defi  ne 
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a combined secretory and proliferative fi  eld that spreads through 
the nongermative epithelia of lacrimal and salivary glands. 
  Because other nongermative epithelia have luminal structures, 
secretory/proliferative fi  elds might be a general principle.
We sought to characterize lacritin’s domain, cell target 
specifi  city, optimal dose, and signaling pathways. We determine 
that lacritin targets only a small subset of epithelia, and not 
 fi broblasts or glia. It does so via a C-terminal domain, which, in 
parallel studies (Ma et al., 2006), appears to require heparanase 
(HPSE) to unblock a binding site in the core protein of 
  coreceptor syndecan-1 (SDC1). Lacritin signaling to PKCα 
  activates both Ca
2+–NFAT and phospholipase D (PLD)–mTOR 
pathways via the Ca
2+ sensor STIM1, suggesting a novel mito-
genic approach for renewal.
Results
Lacritin is a cell-selective mitogen
Lacritin fl  ows over nongermative glandular epithelia of acini 
and ducts to later become deposited on the surface of the eye or 
mouth (Fig. 1 A). The human salivary ductal (HSG) cell response 
to recombinant lacritin is bell-shaped with an optimal dose of 
1 or 10 nM (Fig. S1, available at http://www.jcb.org/cgi/content/
full/jcb.200605140/DC1), promoting a level of proliferation 
often matching the FBS-positive control (Fig. 1 B). This biphasic 
response and dosage is equivalent to that seen for sonic hedge-
hog, VEGF, FGF, and PDGF in other cell systems (Chang et al., 
2004). Few other cell types are targeted by lacritin. Lacritin is 
mitogenic for HCE and human embryonic kidney cells (Fig. 1 B),
which both display a similar bell-shaped response (unpublished 
data). Lacritin does not appear to be mitogenic for human epider-
mal (A431), cervical (HeLa), foreskin fi  broblast (HS68), fi  bro-
sarcoma (HT1080), erythroleukemia (K-562), noninvasive breast 
carcinoma (MCF7), melanoma (SK-MEL and WM-164), Ley-
dig (TM4), Sertoli (TM3), and mouse fi  broblast (NIH3T3) cells 
(Fig. 1 B), or for human glioma (U-1242-MG and U-251-MG)
cells, even at higher doses (unpublished data). Lacritin target-
ing is rapid. Lacritin signaling is apparent within the fi  rst min-
ute by differential and transient tyrosine phosphorylation of at 
least nine different unidentifi  ed phosphoproteins (Fig. 1 C) in 
an equivalent dose-responsive manner (unpublished data) that 
exceeds the moderately high level of endogenous phosphoryla-
tion that is characteristic of these cells. [
3H]TdR uptake is also 
rapid, and it is detectable within 2 h of lacritin addition (unpub-
lished data). Interestingly, p42 and p44 MAPK do not appear 
to be activated (Fig. 1 D), thereby minimizing the possibility 
that lacritin-dependent mitogenesis involves transactivation of 
the EGF pathway, or of another common Ras–MAPK cytokine 
or growth factor pathway.
Lacritin’s C terminus drives mitogenesis
Such cell target specifi  city is unusual. Porter et al. (2003) sug-
gested that the putative breast cancer oncogene dermcidin is a ho-
mologue of lacritin. Comparing both by near optimal alignment 
revealed three weakly homologous regions in the C-  terminal 
half (Smoot et al., 2005), two of which reside in predicted 
α-helices (Fig. 2). Several C- and one N-terminal truncation 
mutants were therefore generated (Fig. 2 A). Mutants lacking 
5 and 10 aa from the C terminus, or 24 aa from the N terminus, 
were fully active. Removal of 5 or 10 more C-terminal amino 
acids (C-15 or C-20), respectively diminished or completely ab-
rogated activity (Fig. 2 B, shown at 10 nM). This pattern is mir-
rored by loss of binding to the core protein of lacritin coreceptor 
SDC1 (Ma et al., 2006). Thus, the 10 additional C-terminal 
amino acids deleted from C-10 (aa 100–109 of mature lacritin; 
Fig. 2 C) are important for both activities. To determine whether 
Figure 1.  Cell target speciﬁ  city of mitogenic 
lacritin. (A) Lacritin released from lacrimal aci-
nar cell secretory granules ﬂ  ows via ducts to 
the surface of the eye. In the salivary gland, 
lacritin is generated by ductal cells and ﬂ  ows 
into saliva. Observations are based on ELISA 
detection of lacritin in human tears or saliva, 
and immunolocalization of lacritin in human 
lacrimal and salivary glands (Sanghi et al., 
2001). (top) Mature recombinant lacritin puri-
ﬁ  ed from Escherichia coli and pLAC construct. 
(B) Lacritin targeting of HSG cells promotes a 
bell-shaped mitogenic response with maximum 
proliferative activity at 1 or 10 nM lacritin, 
similar to that of the 10% FBS–positive control. 
Lacritin also targets downstream HCE and hu-
man embryonic kidney 293 cells. Cell types 
that were not responsive include the following: 
A431, HeLa, HS68, HT1080, K562, MCF7, 
NIH3T3, SKMEL, TM3, TM4, or WM164 cells. 
In other studies, lacritin promotes secretion and 
Ca
2+ mobilization by rat (Sanghi et al., 2001) 
and rabbit (unpublished data) lacrimal acinar 
cells. (C) Tyrosine phosphorylation before and 
1 min after lacritin addition. Accompanying 
densitometric scans follow tyrosine phosphory-
lation over 4 h. (D) p42/p44 are not activated 
by lacritin. Loading control is total glycogen 
synthase kinase β. All experiments performed 
in HSG cells in this and subsequent ﬁ  gures.LACRITIN MITOGENIC SIGNALING • WANG ET AL. 691
this region is capable of α-helical formation, we synthesized the 
active  region  K Q F I E N G S E F A Q K L L KKFS  with  several  fl  ank-
ing amino acids and subjected it to circular dichroism. In PBS 
it formed a random coil, and in 10 mM dodecylphosphocholine 
it formed an α-helix (Fig. 2 D). Although plasma membrane 
(PM) insertion is not in keeping with lacritin’s low nanomolar 
activity and cell specifi  city, hydrophobic surfaces on the same 
or different proteins can create an environment appropriate for 
α-helical formation (Murre et al., 1989). By “helical wheel,” 
5 of 10 residues in the active region are hydrophobic, and all 
group along one face (Fig. 2 E) as an amphipathic α-helix. 
Amphipathic  α-helices are common in ligand–receptor or 
  ligand–ligand interactions. The hydrophobic face of PTHLH’s 
C-terminal amphipathic α-helix, for example, mediates binding 
of PTHR1 (Barden et al., 1997). The same mechanism directs 
VEGF dimerization as a prerequisite for FLT1 and KDR recep-
tor binding (Siemeister et al., 1998).
Distinctive lacritin mitogenic signaling 
through PKC𝗂
How does lacritin signal toward mitogenesis? Lacritin-targeted 
HCE cells rapidly mobilize intracellular Ca
2+ (Sanghi et al., 
2001), and in HSG cells, tyrosine phosphorylation of at least 
nine unidentifi   ed proteins follows within a minute of lacri-
tin addition (Fig. 1 C). p42 and p44 activation were excluded 
(Fig. 1 D), suggesting that lacritin mitogenic signaling was 
likely distinct from the Ras–MAPK pathway common to many 
growth factors and cytokines. Although lacritin binds SDC1 
(Ma et al., 2006), its demonstrated signaling properties are 
  limited. Loading HSG cells with the Ca
2+ indicator Fluo-4 
(Fig. 3) revealed that the mitogenic dose of lacritin (10 nM), but 
not of nonmitogenic C-25 deletion mutant, usually promotes 
Ca
2+ mobilization within 30 s of addition (Fig. 3, A–C, and E). 
  Several common inhibitors were tested (Fig. 3 C). Preincubation 
with 100 ng/ml pertussis toxin (PTX) completely inhibited 
mobilization, suggesting an upstream requirement for active 
G proteins Gαi or Gαo. Cells treated with positive control musca-
rinic agonist carbachol were unaffected (Fig. 3 C). Carbachol’s 
Gαq-mediated pathway is well known to be insensitive to PTX. 
The aminosteroid U73122 was tested next. U73122 inhibits 
G protein–mediated activation of PLC that, in turn, catalyzes 
the formation of IP3 and DAG. 1 μM U73122 inhibited Ca
2+ 
mobilization by both lacritin and carbachol (Fig. 3 C), sug-
gesting that PLC-generated IP3 directs Ca
2+ release from intra-
cellular stores. To test this hypothesis, cells were incubated in 
2-[
3H]myo-inositol for 24 h and then stimulated. IP3 generation 
was detected within 15 s of adding lacritin or carbachol. None 
was formed with C-25 (Fig. S2, available at http://www.jcb.org/
cgi/contents/full/jcb.200605140/DC1). DAG activates down-
stream PKC. Yet, when cells were preincubated with 1 μM of 
the PKC inhibitor Go 6976, lacritin-stimulated Ca
2+ mobiliza-
tion was completely inhibited (Fig. 3 C), suggesting an unusual 
upstream requirement for active PKC. In contrast, mobiliza-
tion was unaffected in positive control carbachol-stimulated 
cells (Fig. 3 C), even at 10 μM Go 6976 (unpublished data). 
  Therefore, lacritin signaling displays distinctive features.
Davies et al. (2000) demonstrated that specifi  cities  of 
protein kinase inhibitors are less narrow than initially thought. 
Although Go 6976 is the most selective of PKC inhibitors, 
in vitro assays reveal the capacity to inhibit elements of the 
MAPK (MKK1 and MAPKAP-K1b), ERK/p38 (MSK1), Rho 
(ROCK2), and Akt (S6K1) pathways, as well as GSK3B down-
stream of Gαq. HSG cells are known to express PKCα, δ, ε, γ, ι, 
and λ (Jung et al., 2000), of which only the α isoform should be 
inhibited by Go 6976 at 1 μM. PKCα mRNA was thus targeted 
for degradation by RNAi (Fig. 4). HSG cells were transfected 
with a pool of four siRNAs for PKCα. PKCα became depleted, 
and transfected cells failed to proliferate in response to lacritin. 
Serum-triggered mitogenesis was slightly reduced (“D7–D10”) 
in comparison to mock and negative controls. Cells were then 
individually transfected with each of the four siRNAs. Both 
PKCα D7 and D10 transfectants were lacritin unresponsive, but 
completely serum responsive in proliferation assays (Fig. 4). 
 Importantly, further testing of D7 revealed no lacritin- dependent 
Ca
2+ mobilization (Fig. 3 C; bottom). We hypothesize that liga-
tion of coreceptor SDC1 (Ma et al., 2006) is coupled to binding 
of a G protein–coupled receptor, thereby successively activating 
Gαi or Gαo, PKCα, and PLC.
Figure 2.  Lacritin’s C-terminal 𝗂-helix is nec-
essary for mitogenesis. (A) Mature lacritin ver-
sus N- and C-terminal deletion constructs. 
Boxed are PSIPRED-predicted α-helices. (B) De-
letion constructs N-24, C-5, C-10, and C-15 
are active; C-20, C-25, and C-59 are inactive. 
Concentration of lacritin and lacritin deletion 
constructs is 10 nM in this and subsequent 
  ﬁ   gures. (C) Activity breakpoint suggests that 
the proximal 2/3 of the more distal of two 
  predicted C-terminal α-helices is essential for 
mitogenesis. A predicted N-linked glycosylation 
site (NGS) binds the N terminus of the distal 
helix. PSIPRED conﬁ   dence numbers for an 
α-helix (H) or random coil (C) are indicated. 
(D) K  Q  F  I  E  N  G  S  E  F  A  Q  K  L  L  K  K  F  S   forms a random 
coil in PBS (dashed line) and an α-helix in 
10 mM dodecylphosphocholine (solid line), 
as examined by circular dichroism. (E) The 
C-terminal  α-helix (N  G  S  E  F  A  Q  K  L  L  K  K  F  S  ) likely 
presents the hydrophobic-binding face “AFGL,” 
as predicted by the helical wheel.JCB • VOLUME 174 • NUMBER 5 • 2006  692
Ca
2+ can be mobilized from sources both inside and out-
side cells. Several simple experiments were performed to gain 
insight. Stimulating cells in Ca
2+-free medium mobilized Ca
2+, 
suggesting internal release. Restoration of extracellular Ca
2+ 
promoted further mobilization (Fig. 3 E), suggesting infl  ux. 
BHQ was tested next. BHQ reversibly inhibits the sarcoplasmic 
reticulum Ca
2+/Mg
2+ ATPase, thereby preventing refi  lling and 
allowing depletion of intracellular ER Ca
2+ stores. 10 μM BHQ 
pretreatment inhibited Ca
2+ mobilization by lacritin (Fig. 3 E), 
suggesting that ER Ca
2+ stores are targeted by lacritin signal-
ing, in keeping with lacritin-dependent IP3 generation (Fig. S2). 
Store-operated Ca
2+ (SOC) infl  ux is the movement of Ca
2+ 
across the PM in response to depleted Ca
2+ stores (Ambudkar, 
2006; Putney, 2005). High concentration 2-APB is an inhibitor 
of SOC infl  ux. When 100 μM 2-APB was added to lacritin- or 
thapsigargin-treated cells at maximal mobilization, suppression 
was immediate (unpublished data). TRPC channels (including 
TRPC1 in HSG cells; Liu et al., 2000) have been proposed to 
be essential for SOC. In two recent comprehensive and inde-
pendent siRNA screens for SOC mediators, the major hits were 
to STIM1 and STIM2 (Roos et al., 2005; Liou et al., 2005). 
To determine whether STIM1 or TRPC1 may play a role in 
 lacritin-dependent  Ca
2+ infl  ux, HSG cells were depleted of 
each by siRNA. Lacritin stimulation of cells in nominally 
Ca
2+-free media, followed by Ca
2+ addition, revealed that infl  ux 
was   suppressed in STIM1-depleted cells (Fig. S3, available at 
http://www.jcb.org/cgi/contents/full/jcb.200605140/DC1).   Infl  ux 
in cells lacking TRPC1 appeared unaffected. Collectively, 
these results suggest that PKCα plays a central role in lacritin 
mitogenic signaling, and that STIM1, but not TRPC1, may 
be   necessary for Ca
2+ infl  ux, possibly via a SOC mechanism. 
Figure 3.  Lacritin’s mitogenic C terminus promotes Ca
2+ mobilization in 
a PTX-inhibitable manner that requires PLC and PKC𝗂. (A) Mobilization 
of intracellular Ca
2+ 20–30 s after lacritin (lacrt), but not C-25, addition 
(cells in Ca
2+-containing medium for this and subsequent ﬁ  gures, unless 
indicated otherwise). (B) Apparent initial nuclear mobilization (circled) or 
a combination of cytoplasmic and nuclear mobilization because this is 
the thickest part of the cell. (C) Ca
2+ ﬂ  uorescence tracings after addition 
(arrow) of lacritin, C-25, vehicle (vehic), or positive control carbachol (cch) 
in the absence or presence of inhibitors. Ca
2+ mobilization in response to 
lacritin is observed in most cells per ﬁ  eld at 1 or 10 nM and is suppressed 
by pretreatment with PTX, U73122, Go 6976, or by siRNA depletion 
of PKCα. Carbachol-dependent mobilization is unaffected by PTX or 
Go 6976. (D) Fluorescence quantitation of apparent nuclear (see note in 
(B) above) versus cytoplasmic signal (11–17 cells). (E) Ca
2+ mobilization 
with or without Ca
2+ and 10 μM BHQ pretreatment. Cells pretreated with 
BHQ in Ca
2+-free medium just before the addition of 10 nM lacritin in the 
same medium (18–27 cells). Bars: (A) 50 μm; (B) 25 μm.
Figure 4.  PKC𝗂 is necessary for lacritin-dependent mitogenesis. 
(A) siRNA depletion of PKCα eliminates lacritin’s mitogenic response, as ob-
served with pooled siRNAs D7–10, and D7 and D10 applied   individually. 
Little or no effect on FBS-stimulated mitogenesis, or on negative control 
lamin A/C siRNA, is observed. PKCα blot illustrates protein depletion with 
D7–10, but not in mock-transfected (mk) or lamin A/C siRNA-transfected 
cells (ng). Data are presented as the mean ± the SEM. Asterisks represent 
inhibitory siRNAs. (B) PKCα knockdown via D7 is visualized by anti-PKC 
immunoﬂ  uorescence. Bar, 50 μm.LACRITIN MITOGENIC SIGNALING • WANG ET AL. 693
This pattern was later confi  rmed in NFAT translocation and 
 mitogenesis  experiments.
Lacritin stimulates translocation of PKC𝗂 
to the perinuclear Golgi region (PNG)
PKCα regulation of cell proliferation is initiated by trans-
location of cytoplasmic PKCα to membranes. Interaction of 
membrane-associated PKCα with other membrane-associated 
effectors drives downstream signaling to mitogenesis. To appre-
ciate how lacritin mitogenic signaling is transduced in the con-
text of Ca
2+ mobilization, we asked whether lacritin promotes 
PKCα translocation and, if so, to which membrane compartment. 
PKCα was imaged in cells 15 min after treatment (Fig. 5 A). 
10 nM nonmitogenic C-25 had no effect, leaving PKCα dif-
fusely distributed throughout the cytoplasm. In contrast, 10 nM 
lacritin or N-24 shifted PKCα primarily to the PNG, as con-
fi  rmed by colocalization with the Golgi marker mannosidase II 
(Fig. 5 B). Cells treated with positive control PMA concentrated 
PKCα solely in the PM (unpublished data). The phosphoryla-
tion state of PKCα infl  uences its translocation site. Hyperphos-
phorylated PKCα becomes associated with the PM, whereas 
hypophosphorylated or dephosphorylated PKCα is known to 
translocate to the PNG (Hu and Exton, 2004). To determine if 
the latter is true and, if so, over what time course, cells were 
treated with lacritin, N-24, and C-25. Cell lysates were then 
blotted for phospho-PKCα (Fig. 6). 10 nM lacritin promotes 
PKCα dephosphorylation within 1 min of addition. This form 
is sustained for at least 15 min, but by 30 min has returned to 
baseline phosphorylation. Dephosphorylation triggered by in-
creasing molar levels of lacritin or N-24 mirrored the prolifera-
tion response, with optimal dephosphorylation at 1 or 10 nM. 
Nonmitogenic C-25 had no effect, whereas positive control 
PMA promoted some phosphorylation. It was suggested that 
lacritin-stimulated signaling toward Ca
2+ mobilization follows 
a Gαi or Gαo–PKCα–PLC pathway. If so, PTX and Go 6976, 
but not U73122 should inhibit PKCα translocation. We retested 
each and observed that lacritin-dependent PKCα translocation 
and dephosphorylation were inhibited by 100 ng/ml PTX and 
1 μM Go 6976, but also by 1 μM U73122 (Fig. 5 A). The weakly 
active analogue U73343 is often used as a negative control for 
U73122. Cells preincubated with 1 μM U73343 displayed full 
translocation (Fig. 5 A). This implies that an interdependent 
complex of PKCα and PLC may be intermediate between Gαi or 
Gαo activation and PKCα translocation, most logically in the PM. 
Yet as early as 1 min, PKCα was dephosphorylated, and there-
fore likely already translocated to the PNG. An alternative pos-
sibility is that a PLC isomer is stationed in the PNG and when 
active serves to capture translocating PKCα. PLCγ2 is concen-
trated in the PNG in mast cells before and after antigen stimu-
lation (Barker et al., 1998). Is PLCγ2 or another PLC isomer 
located in the PNG of HSG cells and, if so, does it complex 
with PKCα? Cells were treated for 15 min with 10 nM lacritin, 
and then immunostained for PKCα and PLCγ2 (Fig. 7). PLCγ2 
displays a discrete perinuclear Golgi localization, which par-
tially overlaps with PKCα (Fig. 7 A), suggesting that the two 
are in suffi  cient proximity to form a signaling complex. The 
existence of a PLCγ2–PKCα complex was, including some 
 activated  PLCγ2, confi  rmed by anti-PLCγ2 immunoprecipitation
(Fig. 7, B and C).
Downstream activation of PLD
We propose that translocation of hypophosphorylated PKCα 
to the PNG is anchored by an interdependent complex with 
active PLCγ2. Local generation of IP3 then may drive Ca
2+ 
Figure 5.  Lacritin stimulates translocation of PKC𝗂 to the PNG and NFATC1 
to the nucleus, both in a G𝗂i- or G𝗂o- and PLC-dependent manner. (A) Lac-
ritin and N-24, but not C-25, promotes translocation of PKCα to the PNG 
and NFATC1 to the nucleus. Lacritin-dependent translocation of PKCα and 
NFATC1 are inhibited by PTX, U73122, and Go 6976; but not by inactive 
U73122 analogue U73343, nor nifedipine (nifed). Translocation at 
15 min with 10 nM lacritin is shown. Bar, 25 μm. (B) Translocated PKCα 
partially colocalizes with the Golgi marker mannosidase II (ManII; same 
time and dose as in A). Bar, 10 μm.JCB • VOLUME 174 • NUMBER 5 • 2006  694
 mobilization, followed by extracellular Ca
2+ entry via a STIM1-
regulated mechanism. Could other effectors be activated from 
this site? Recently, Hu and Exton (2004) linked perinuclear 
translocation of hypophosphorylated PKCα to activation of 
PLD1 via a protein–protein interaction. PLD1 is most concen-
trated in the PNG and plays a key role in cell proliferation and 
secretion (for review see Foster and Xu, 2003), which are both 
functions of lacritin. Therefore, we hypothesized that lacritin-
stimulated translocation of hypophosphorylated PKCα acti-
vates perinuclear Golgi PLD to, in turn, generate phosphatidic 
acid by hydrolysis of phosphatidylcholine. Endogenous PLD 
activity was measured. After lacritin addition, PLD displays 
a bell-shaped activation curve that was optimal at 10 nM lac-
ritin (Fig. 7 D), thus, recapitulating the same dose dependency 
observed for mitogenesis, PKCα translocation, and PKCα 
  dephosphorylation. To ask whether PKCα was upstream of PLD 
in lacritin signaling, cells were transfected with D7 siRNA. 
Depletion of PKCα completely abrogated PLD activation in 
response to lacritin, whereas PLD activation by serum was 
  unaffected (Fig. 7 D). By confocal microscopy, PLD1 displays 
a broader perinuclear, and partially nuclear, distribution that 
partially colocalizes with PKCα in lacritin-stimulated cells 
(Fig. 7 A). Both are detected in anti-PLCγ2   immunoprecipitates 
(Fig. 7 A).   Therefore, it appears that transiently hypophos-
phorylated perinuclear Golgi PKCα complexes with PLCγ2 to 
perform at least two roles. It triggers IP3 generation and Ca
2+ 
mobilization, and it also activates PLD1.
Common upstream signals diverge
Downstream lacritin signaling toward cell cycle progression 
may follow at least two different pathways. First, the promi-
nence of Ca
2+ mobilization raises the possibility that cytoplas-
mic Ca
2+ may stimulate the phosphatase calcineurin to activate 
cytoplasmic NFAT. Dephosphorylated NFAT translocates into 
the nucleus, where it binds DNA in an obligatory cooperative 
interaction with other transcription factors including Fos, Jun, 
GATA, and C/EBP. Second, because lacritin signaling activates 
PLD1 (Fig. 7 D) and active PLD1 generates phosphatidic acid, 
it is possible that lacritin signals to the mitogenic phosphatidic 
acid–mTOR–p70 S6 kinase 1 pathway (Fang et al., 2003). 
Figure 6.  Lacritin-dependent PKC𝗂 dephosphorylation is temporally 
linked with perinuclear Golgi translocation. Western blots illustrating dose- 
and time-dependent dephosphorylation of PKCα in response to lacritin or 
N-24, but not C-25. Total PKCα protein serves as loading control.
Figure 7.  Translocated PKC𝗂 becomes associated with PLC𝗄2 and acti-
vates PLD1. (A) Perinuclear colocalization of PKCα with PLCγ2; and PKC 
with PLD1 15 min after lacritin addition. Bars, 25 μm (left) and 10 μm 
(right). (B) Anti-PLCγ2 immunoprecipitate of homogenate from cells treated 
for 15 min with lacritin contains PKCα and PLD1. (C) Lacritin dose–
response analysis of PLCγ2 phosphorylation in anti-PLCγ2 immunoprecipi-
tates of homogenate from 15-min–treated cells. (D) Lacritin addition 
promotes activation of PLD in a biphasic dose-dependent manner. Activa-
tion is abrogated by knockdown of PKCα using siRNA D7, which has little 
or no effect on FBS-stimulated PLD activation. Data are presented as the 
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  Hypothetically, both pathways could be additively required 
for lacritin mitogenesis, as per parallel ERK and mTOR 
  mitogenic signaling in response to FGF-9 (Wing et al., 2005). 
  Alternatively, one may modulate the other, as per PI(3)K/
Akt inhibition of calcineurin in muscle IGF-1 signaling 
(Rommel et al., 2001). The fi  rst question was whether cal-
cineurin is   activated. Dose response assays revealed that lac-
ritin   activated calcineurin in a biphasic manner (Fig. 8 A) 
within 1 min of addition and was substantially reduced at 
30 min (unpublished data). 10 nM nonmitogenic C-25 had no 
effect, whereas N-24 was activating (Fig. 8 A). Activation was 
dependent on PKCα and STIM1, but not TRPC1, and was in-
hibited by cyclosporin A (CsA; Fig. 8 D). Because NFAT in 
lacrimal, salivary gland, or corneal epithelia has not previously 
been studied, we chose to examine NFATC1, which is the only 
NFAT isomer selectively up-regulated in the proliferative 
compartment of skin epithelium (Tumbar et al., 2004). We 
localized NFATC1 in cells 15 min after treatment (Fig. 5 A). 
10 nM nonmitogenic C-25 had no effect; NFATC1 was diffusely 
distributed throughout the cytoplasm. In contrast, 10 nM lac-
ritin or N-24 shifted NFATC1 to the nucleus. For verifi  cation 
and to follow the dose response and time course, cells were 
treated with lacritin, N-24, and C-25, and then purifi  ed nuclei 
blotted for NFATC1 (Fig. 8, B and C). 10 nM lacritin promoted 
NFAT translocation within 1 min of addition. Translocation 
was sustained for 30 min. As per PKCα, PLD, and mitogenic 
responses, 1 or 10 nM lacritin was optimal. In contrast, the 
Ca
2+ dose response is sigmoidal (unpublished data). This sug-
gests that a step associated with calcineurin is responsible for 
the sigmoidal-to-biphasic transition. To ask whether NFATC1 
translocation was downstream of Gαi or Gαo, PKCα and PLC 
cells were treated with each of the inhibitors. Translocation 
was inhibited by PTX, U73122, and Go 6976, but not by the 
negative control U73343 (Fig. 5 A). Cells transfected with 
siRNA for PKCα or STIM1 (but not for TRPC1) were also 
incapable of lacritin-dependent NFATC1 translocation, as were 
cells in EGTA (Fig. 9 A). This could be quantitated at the cellu-
lar level (Fig. S4, available at http://www.jcb.org/cgi/contents/
full/jcb.200605140/DC1). As noted, Ca
2+-activated calcineu-
rin promotes NFATC1   translocation. CsA inhibits calcineurin 
(Fig. 8 D). Addition of 1 μM CsA to cells completely blocked 
lacritin-dependent NFATC1 translocation (Fig. 9 A). To ask 
whether this pathway is mitogenic, 1 μM CsA was included 
in the proliferation assay. Other cells were depleted of NFATC1 
or STIM1 by siRNA. All three approaches blocked lacritin-
stimulated mitogenesis (Fig. 9, C and D). PTX, U73122, and 
Go 6976, but not U73343, nifedipine (unpublished data), or de-
pletion of TRPC1 (Fig. 9 C), also blocked mitogenesis. Thus, 
mitogenesis via lacritin-induced NFATC1 translocation appears 
to be downstream of Gαi or Gαo–PKCα-PLC–Ca
2+–calcineurin. 
Moreover, upstream STIM1 appears to be essential as a regula-
tor of Ca
2+ infl  ux necessary for NFATC1 translocation.
Downstream effectors of activated NFAT include cyclo-
oxygenase-2 (COX2), IL6, and OSCAR, but which effectors 
would be targeted in HSG cells was unknown. By RT-PCR, 
only COX2 is affected (Fig. 9 B). Lacritin-induced COX2 ex-
pression is inhibited by CsA and reduced in NFATC1-depleted 
cells. COX2 expression is associated with enhanced epithelial 
proliferation and decreased apoptosis (Slice et al., 2005).
Recently, Fang et al. (2003) demonstrated that phosphat-
idic acid generated by PLD1 activates the rapamycin-sensitive 
mTOR–pS6K1 pathway. mTOR–pS6K1 regulates mitogenicity 
and cell growth by promoting protein translation necessary for 
G1 cell cycle transition (Lane et al., 1993). Preincubation of 
cells with 100 nM of the mTOR inhibitor rapamycin (Fig. 9 D) 
or depletion of mTOR (Fig. 9 C) by siRNA was inhibitory. Both 
also suppressed COX2 expression (Fig. 9 B). Recently phospho-
activated RSK was found to bind and stabilize an activated 
NFATC4–DNA complex, thereby contributing to transcriptional 
activation (Yang et al., 2005). Phosphorylation of RSK is 
  rapamycin-insensitive and downstream of p42/p44. In Fig. 1 D, 
we showed that p42/p44 is not activated by lacritin. In keeping 
with this result, no evidence of RSK activation could be detected 
in lacritin-treated cells (unpublished data). Collectively, these 
data suggest that mitogenic Gαi or Gαo–PKCα-PLC–Ca
2+–
  calcineurin–NFATC1 and Gαi or Gαo–PKCα-PLC–Ca
2+–
  calcineurin–PLD1–mTOR pathways are triggered by lacritin 
via STIM1 activation (Fig. 10). 
Figure 8.  Time- and dose-dependent activation of calcineurin and ap-
pearance of NFATC1 in puriﬁ  ed nuclei. (A) 10 nM lacritin promotes peak 
calcineurin activity, whereas 10 nM C-25 has no effect. N-24 is also 
  active. (B) Nuclear NFATC1 is detected after treating cells with lacritin or 
N-24, but not with C-25. Dose response is identical to that for calcineurin. 
Nuclear protein Ran serves as loading control. (C) Time course for   lacritin-
dependent NFATC1 translocation. (D) Lacritin-dependent calcineurin acti-
vation is inhibited by CsA, and is dependent on PKCα and STIM1, but not 
TRPC1. Data are presented as the mean ± the SEM.JCB • VOLUME 174 • NUMBER 5 • 2006  696
Discussion
We document that lacritin is mitogenic for a small subset of 
epithelial cell lines derived mainly from the nongermative ep-
ithelia that normally contact lacritin during its outward glan-
dular fl  ow. This activity is dependent on a C-terminal domain 
that indirectly activates NFAT and mTOR mitogenic path-
ways through shared Gαi or Gαo, PKCα, PLC, and STIM1-
regulated Ca
2+ signaling (Fig. 10). The possibility that lacritin 
transactivates another growth factor pathway involving Rho-
MAPK appears to be ruled out by lack of MAPK1/MAPK2 
and pRSK activation.
Like the Wnt–Ca
2+ pathway, lacritin signaling is PTX-
sensitive and involves NFAT. NFATC1 regulates prostate cancer 
cell expression of prostate-specifi   c membrane antigen (Lee 
et al., 2003), smooth muscle proliferation in response to PDGF, 
and lymphocytic cell cycle progression (Caetano et al., 2002). 
Linkage of mTOR signaling to cell proliferation has been docu-
mented in stem cells of the cerebral cortical proliferative zone 
(Sinor and Lillien, 2004), CD133(+) bone marrow–derived en-
dothelial precursors (Butzal et al., 2004), and, to a considerable 
extent, in embryonic stem cells of preimplantation embryos 
(Gangloff et al., 2004). Thus, each plays key roles in cell 
  proliferation. Upstream PKCα signaling differs. Wnt5a pro-
motes translocation of PKCα to the PM (Sheldahl et al., 1999), 
whereas lacritin signaling (Fig. 10) appears to stimulate the 
  formation of a transient perinuclear Golgi complex of PKCα, 
PLD1, and PLCγ2. This activates PLD1 of the mTOR pathway. 
Some PLCγ2 activation and considerable IP3 generation were 
detected. Ca
2+ mobilization may then be a direct spatiotem-
poral consequence of PKCα perinuclear Golgi translocation 
via local generation of IP3 – thereby placing PKCα upstream of 
Ca
2+. The exact mechanism is unclear. Although supported by 
PKCα knockdown, Go 6976 suppression can, for example, 
seem   contradictory at fi  rst glance. Normally, Go 6976 opposes 
PKCα phosphorylation as a competitive inhibitor of ATP bind-
ing to PKCα’s catalytic domain, whereas in lacritin-treated cells 
the opposite appears to be true. Mirroring our observation, the 
PKCα inhibitors RO and Bis-1 prevent dephosphorylation of 
PKCα and translocation to the PNG after PMA treatment of 
Figure 9.  Ca
2+ sensor STIM1, but not the 
Ca
2+ channel subunit TRPC1, is required for 
lacritin-dependent NFATC1 translocation and 
mitogenesis. (A) Western blots of puriﬁ  ed nu-
clei revealing that lacritin-dependent NFATC1 
translocation is inhibited by extracellular EGTA 
and CsA and requires PKCα and STIM1, but 
not TRPC1. siRNA depletion of mTOR may 
slightly decrease NFATC1. (B) Lacritin promotes 
COX2 mRNA expression downstream of both 
NFAT and mTOR, as suggested by respec-
tive CsA and rapamycin inhibition. Similarly, 
COX2 expression is decreased or absent in 
cells depleted of NFATC1 and mTOR. (C) Cells 
depleted of NFATC1, mTOR, or STIM1, but not 
TRPC1, display little or no lacritin mitogenesis. 
(D) CsA and rapamycin both inhibit lacritin-
  dependent mitogenesis.
Figure 10.  Proposed model of lacritin mitogenic signaling pathway lacri-
tin signaling suggested by data outlined in the text. Involvement of HPSE 
(“Hep’ase”) to unblock a lacritin-binding site on SDC1 is from Ma et al. 
(2006). “?” indicates putative GPCR or ion channel. Dashed lines and 
items in italics are presumed. PKCα’s role upstream of calcineurin (Calcin) 
is not shown for simplicity.LACRITIN MITOGENIC SIGNALING • WANG ET AL. 697
COS-7 cells (a system in which PKCα translocates to both PM 
and Golgi). Hu and Exton (2004) accordingly proposed that RO 
and Bis-1 may be acting as inhibitors of dephosphorylation or 
inducers of phosphorylation via another protein kinase or phos-
phatase, as is also likely the case for Go 6976. Interestingly, Go 
6976 is also capable of suppressing the activity (Davies et al., 
2000) of the mTOR effector and inhibitor S6K1 (Holz and Blenis, 
2005), but this is likely inconsequential to lacritin signaling. 
PKCα is also upstream of calcineurin, and it is possible that bi-
phasic PKCα-dependent regulation of the calcineurin inhibitor 
DSCR1 may drive calcineurin’s biphasic response to lacritin. 
This would effectively transform the Ca
2+ sigmoidal response 
into the observed biphasic mitogenic response.
Lacritin also promotes COX2 expression as a downstream 
consequence of NFATC1 activation. Both NFAT and mTOR in-
hibitors appear to suppress expression (Fig. 9 B). This raises 
the possibility that NFAT and mTOR mitogenic pathways might 
overlap before COX2 transcription in HSG cells. COX2 is also 
widely linked to epithelial proliferation and survival (Slice 
et al., 2005), and, when dysregulated, to epithelial tumors. Mice 
transgenic for COX2 display sebaceous gland hyperplasia when 
expression is driven by the keratin 5 promoter (Neufang et al., 
2001) and enhanced mammary alveolar differentiation when 
controlled by the MMTV promoter (Liu et al., 2001). Both con-
ditions are associated with enhanced secretory product (lipid or 
β-casein, respectively), independent of an effect on cell number. 
Because lacritin is both mitogenic and prosecretory, it is 
  possible that COX2 might mediate both functions. This pos-
sibility is in keeping with new lacritin studies suggesting that 
the prosecretory and mitogenic dose–response curves might 
overlap in HCE cells (unpublished data). On the other hand, 
10 nM lacritin did not promote amylase expression (unpublished 
data) by HSG cells that, for mitogenic studies, were routinely 
plated on plastic, or in Ca
2+ signaling for only short periods 
on a thin basement membrane coating. Others have shown that 
HSG cells require several days of growth on a thicker basement 
membrane substratum to promote amylase production and cell 
polarization (Hoffman et al., 1996). Secretory vesicles (Royce 
et al., 1993) are detected together with the formation of acinar-
like structures.
The discovery of STIM1 and, very recently, Orai1 as 
being, together, essential for SOC infl  ux (Peinelt et al., 2006; 
  Soboloff et al., 2006) opens new areas of investigation. STIM1 
undergoes ER to PM or near-PM translocation regulated by its 
Ca
2+-binding EF hand (Liou et al., 2005; Zhang et al., 2005). 
Orai1 is thought to form or help form the Ca
2+ channel. TRPC1 
is considered to be a SOC candidate (Ambudkar, 2006). 
TRPC1 is endogenously expressed in HSG cells, and when sta-
bly overexpressed enhances SOC infl  ux, unlike overexpression 
of TRPC3 (Liu et al., 2000). Why would depletion of TRPC1 
have no effect on lacritin-induced Ca
2+ infl  ux, NFATC1 trans-
location, or mitogenesis; or on SOC in the thapsigargin-treated 
cells of Roos et al. (2005) and Liou et al. (2005)? Possibly 
another TRPC compensates (i.e., TRPC3 at low levels is store 
operated; Vazquez et al., 2003), although SOC was not affected 
by coordinated targeting of all three Drosophila melanogaster 
trp genes (Roos et al., 2005). We ruled out the possibility that 
siRNA depletion was not complete (Fig. S3 A). TRPC1 may 
turnover relatively slowly and, thus, protein levels might take 
longer to lower, yet recent 80 nM siRNA depletion of TRPC1 
protein in IEC cells was almost and entirely complete by 
24 and 48 h, respectively (Marasa et al., 2006). Because 
we have not examined the effect of siSTIM1 or siTRPCI on 
thapsigargin-stimulated Ca
2+ entry or NFAT activation, it is 
possible that the mechanism observed is relatively specifi  c for 
lacritin. FBS stimulation was unaffected by both depletions. 
Early studies suggested that STIM1 overexpression affects cell 
phenotype and adhesion without diminishing viability (Oritani 
and   Kincade, 1996) or, contrastingly, is apoptotic (Manji et al., 
2000). We observed no apparent affect of STIM1 depletion on 
adhesion, and have found lacritin to be antiapoptotic (unpub-
lished data). Future studies seeking to move lacritin from HSG 
cells to mouse models and primary cultures of dispersed glands 
(Luo et al., 2001) provide an opportunity to explore these inter-
related observations. How does lacritin selectively target some, 
but not other, epithelia? New data suggests a novel mechanism 
in which extracellular HPSE unblocks a lacritin-binding site 
on the core protein of SDC1 (Ma et al., 2006). This transforms 
a widely expressed cell surface proteoglycan into a selective 
coreceptor that hypothetically presents lacritin to a lower af-
fi  nity signaling receptor. siRNA depletion of HPSE abrogates 
lacritin-dependent, but not EGF-dependent, mitogenesis. In 
pull-down assays, SDC1 core protein binding maps to lacritin’s 
mitogenic domain. Neither syndecans-2 nor -4 bind lacritin, in 
keeping with poor ectodomain conservation. Immunostaining 
for SDC1 in human lacrimal gland reveals a basolateral distri-
bution that appears to reach to the apical surface (unpublished 
data). HPSE cleavage of heparan sulfate is associated with 
follicular stem cell migration in mouse skin (Zcharia et al., 
2005) and when added exogenously inhibits stroma-induced 
quiescence of bone marrow stem cells (Gordon et al., 1997). 
Whether lacritin can act on corneal/limbal stem cells as it fl  ows 
onto the eye is not known. Lacritin’s HPSE-dependent binding 
of SDC1 ectodomain contrasts with heparan sulfate–binding 
growth factors such as FGF’s, Wnts, and hedgehogs, which do 
not appear to discriminate among syndecans or other heparan 
sulfate proteoglycans. By limiting availability of HPSE, lacri-
tin can hypothetically target fewer differentiated epithelia as it 
fl  ows downstream.
Like lacritin, several other mitogens are secreted apically, 
including TGFβ1 (Murphy et al., 2004), neurotrophin (Yeaman 
et al., 1997), and VEGF (Hornung et al., 1998), as well as EGFs, 
TGFs, HGF, and FGFs, and have all been detected in lacrimal 
and salivary ductal secretions. Although apical membranes are 
not commonly considered to be receptor-rich, CD-44 ( mammary 
gland, salivary gland, and pancreas) nucleates MMP7 and pro–
HB-EGF in an apical complex with ErbB4 are necessary for 
  epithelial cell survival (for review see Wang and Laurie, 2004). 
The M3 muscarinic receptor is apically concentrated in exo-
crine pancreas (Luo et al., 2005), and polarized MDCK cells 
sort nerve growth factor receptor to the apical surface (Yeaman 
et al., 1997). Such outward mitogenic fl  ow from secretory cells 
through ducts of nongermative epithelia could potentially regu-
late secretory physiology and cellular renewal.JCB • VOLUME 174 • NUMBER 5 • 2006  698
Materials and methods
Cell lines
Human salivary ductal cells (HSG) were expanded in DME with 10% FCS 
(Sanghi et al., 2001) or, for mitogenesis experiments, in MEM (Eagle’s 
α modiﬁ  cation). Other cells were grown as per American Type Culture Col-
lection guidelines. All media were purchased from Invitrogen.
Lacritin constructs and puriﬁ  cation
A 363-bp region of DNA coding for intact mature lacritin without signal 
peptide was PCR-ampliﬁ  ed from lacritin cDNA and subcloned into pTYB1 
(New England Biolabs, Inc.) as the lacritin–intein fusion plasmid “pLAC.” 
Respective additions of SapI to forward primer 5′-G  G  T  G  G  T  C  A  T  A  T  G  G  A  A-
G  A  T  G  C  C  -3′ and of NdeI to reverse primer 5′-G  G  T  G  G  T  T  G  C  T  C  T  T  C  C  G  C  A-
T  G  C  C  C  A  T  G  G  -3′ facilitated subcloning. C-terminal deletions of 5, 10, 15, 
20, 25, and 59 aa were generated using forward primer 5′ -G  G  T  G  G  T  T-
G  C  T  C  T  T  C  C  A  A  C  T  A  T  T  A  T  T  A  C  T  A  T  G  A  A  G  A  T  G  C  C  T  C  C  T  C  T  -3′ and the reverse 
primers 5′-G  G  T  G  G  T  G  A  A  T  T  C  T  C  A  T  A  G  A  C  T  G  A  A  T  T  -3′, 5′-G  G  T  G  G  T  G  A  A  T  T-
C  T  C  A  C  A  G  T  A  A  T  T  T  T  T  G  -3′, 5′-G  G  T  G  G  T  G  A  A  T  T  C  T  C  A  A  A  A  T  T  C  A  C  T  T  C  C  -3′, 
5′-G  G  T  G  G  T  G  A  A  T  T  C  T  C  A  T  T  C  G  A  T  G  A  A  T  T  C  -3′, 5′-G  G  T  G  G  T  G  A  A  T  T  C  T  C  A  T-
T  C  A  C  C  T  G  G  C  A  -3′, and 5′-G  G  T  G  G  T  G  A  A  T  T  C  T  C  A  C  T  G  C  C  T  G  C  T  T  G  -3′, 
  respectively. Amplicons were directionally subcloned into pTYB11 using SapI 
and EcoRI as “pLAC/C-5 – pLAC/C-59.” Forward and reverse primers for 
the N-24–terminal deletion were 5′-G  G  T  G  G  T  T  G  C  T  C  T  T  C  C  A  A  C  A  T  C  T  C  A  G-
G  T  C  C  A  G  C  A  G  A  A  C  -3′ and 5′-G  G  T  G  G  T  T  G  C  T  C  T  T  C  C  G  C  A  T  G  C  C  C  A  T  G  G  -3′, 
respectively, creating the plasmid “pLAC/N-24.” All constructs were veri-
ﬁ  ed by sequencing.
Bacterial protein expression was performed using standard 
procedures. Cleared cell lysates were loaded on chitin columns (IMPACT-
CN System; New England Biolabs, Inc.) and equilibrated with 50 mM Tris, 
0.5 M NaCl, pH 8.0, followed by 20-column volumes of washing, elution 
with 50 mM DTT for 16 h at RT in the same buffer, extensive dialysis 
against PBS (4°C), and protein quantitation. The size of lacritin from pLAC 
is 18 kD (12.3 kD predicted) versus 23 kD from pET28b (18.4 kD pre-
dicted with His tag plus signal peptide; previously indicated in error as 
greater in Sanghi et al. [2001]). Mass spectrometry sequencing, and 
  immunoblotting conﬁ  rmed protein identity. Circular dichroism analysis was 
performed in a spectropolarimeter running numerical analysis software 
(AVIV 215 and Igor Pro, respectively; both Wyatt Technology, Corp.).
Phosphotyrosine blotting and mitogenesis
Cells in serum-containing media were seeded overnight in 24-well plates 
at a density of 0.5 × 10
5 cells/mm
2 corresponding to 20–30% conﬂ  u-
ency after cell attachment (see optimization experiments in Fig. S1). Cells 
were then incubated in serum-free (SF) media without supplements for 24 h 
(phosphotyrosine), or washed with SF media without supplements three 
times (mitogenesis) and then incubated with lacritin (1–1,000 nM). In pos-
itive controls, cells were incubated with 1.6 nM EGF or 10% FBS. In neg-
ative controls, cells were incubated with BSA or without additive in SF 
media without supplements. Duration of incubation with lacritin, or with 
negative or positive controls, was for the indicated times (  phosphotyrosine) 
or for 30 h (mitogenesis). In phosphotyrosine assays, cells were extracted 
in 1% NP-40 containing sodium vanadate, 5 mg/ml DTT, protease in-
hibitors, 50 mM Hepes, 100 mM NaCl, and 2 mM EDTA; the cells were 
then separated by 2 mg/ml 10% SDS PAGE, transferred, and blotted. 
  Antiphosphotyrosine antibody (P-Tyr-100), anti–phoshpo-PKCαβII, anti-PKCα, 
anti-p44/p42 MAPK, anti-PLCγ2, and anti-GSK were purchased from Cell 
Signaling Technology. After washing, bound antibodies were detected 
with peroxidase-labeled secondary antibody and ECL. For mitogenesis, 
2 μCi/ml [
3H]TdR was added for an additional 6 h. Labeling was stopped 
with ice-cold PBS and followed by addition of cold and RT TCA (10%) for 
10 min each. After washing, radioactivity was quantitated in a scintilla-
tion counter. For PKCα depletion, a pool of four PKCα-speciﬁ  c siRNAs or 
individual siRNAs (100 nM; Millipore) were transfected into HSG cells 
via Lipofectamine 2000 in Opti-MEMI Reduced Serum medium (Invitrogen) 
in the absence of serum and antibiotics, according to the manufacturer’s 
  instructions. PKCα depletion was conﬁ   rmed by Western blotting. Other 
cells were transfected with pools of NFATC1-, TRPC1-, mTOR-, or STIM1-
speciﬁ  c siRNAs. In negative controls, cells were transfected with a pool of 
four   lamin-speciﬁ  c siRNAs (all 100 nM; Dharmacon Inc.). 72 h after trans-
fection, mitogenesis was assessed by coaddition of 10 nM lacritin and 
2 mCi/ml [
3H]TdR (GE Healthcare) for 24 h. For rapamycin and CsA inhi-
bition, cells that had been incubated in SF media overnight were treated 
with 1 μM CsA (Sigma-Aldrich) for 5 h, 100 nM rapamycin (Calbiochem) 
for 15 min, or both; they were then stimulated with 10 nM lacritin in the 
same medium with 2 mCi/ml [
3H]TdR for an additional 24 h. For RT-PCR 
analyses, total RNAs from cells were reverse transcribed (RETROscript; 
  Ambion) and subjected to PCR using Super Taq DNA polymerase (Ambion) 
for 10 min at 95°C, followed by 35 cycles for 45 s at 95°C, 45 s at 55°C, 
and 90 s at 72°C. Primers used were: (COX2 forward) 5′-A  A  T  T  T  A  A  C  A-
C  C  C  T  C  T  A  T  C  A  C  T  G  G  C  -3′ and 5′-A  A  T  T  G  A  G  G  C  A  G  T  G  T  T  G  A  T  G  A  T  T  T  G  A  A  -3′ 
(COX2 reverse); (IL-6 forward) 5′-G  A  C  A  G  C  C  A  C  T  C  A  C  C  T  C  T  T  C  A  -3′, and 
(IL-6 reverse) 5′-T  C  T  G  G  C  T  T  G  T  T  C  C  T  C  A  C  T  A  C  T  C  T  C  A  -3′; and (GAPDH 
forward) 5′-G  T  C  G  G  A  G  T  C  A  A  C  G  G  A  T  T  T  G  G  T  -3′ and (GAPDH reverse) 
5′-T  C  A  T  G  A  G  C  C  C  T  T  C  C  A  C  G  A  T  G  C  C  -3′. PLD activity was measured as pre-
viously described by Santy and Casanova (2001). For immuno  precipitation 
experiments, cells were lacritin treated for 15 min, lysed with protease in-
hibitors, spun, precleared using protein A–Sepharose, and then subjected 
to anti-PLCγ2 afﬁ  nity precipitation. Precipitates were separated by 10% 
SDS-PAGE gels, transferred, and blotted using standard assays.
Ca
2+ translocation and colocalization analyses
Cells were seeded at 1.4 or 0.7 × 10
4 cells/mm
2 on Matrigel-coated cov-
erslips (100 μg/ml; BD Biosciences) to respectively achieve 70–80% con-
ﬂ  uency after overnight or 48-h growth in 6-well plates containing phenol 
red–free DME with 10% FCS. Cells were washed repeatedly in Ca
2+/phe-
nol red–free HBSS with 20 mM Hepes (Invitrogen), and then incubated for 
10 min in the same solution containing 1 μM U73122, 1 μM U73343 
(BIOMOL Research Labs), 1 μM Go 6976, or 10 μM nifedipine (Calbio-
chem); or for control in vehicle (DMSO/Pluronic diluted to same level in 
  inhibitor solution) alone. Other cells were incubated (0.7 × 10
4 HSG 
cells/mm
2 overnight plating) with 100 ng/ml PTX (Calbiochem) in phenol 
red–free DME with 10% FCS or with vehicle alone). Cells were washed 
with Ca
2+/phenol red–free HBSS and 20 mM Hepes, and then incubated 
for 1 h at RT with the same solution containing Fluo-4 AM at 4 μM (Fluoro-
Pure grade [Invitrogen] dissolved in DMSO plus 20% Pluronic F-127). Cells 
were washed three times for 60 min at RT with Ca
2+/phenol red–free 
HBSS with 5 mM Ca
2+ or EGTA. Temperature was stabilized for 5 min at 
37°C, and then coverslips were placed on the stage of an epiﬂ  uorescent 
microscope (TE300; Nikon; located in the W.M. Keck Center for Cellular 
Imaging at the University of Virginia). TE300 was coupled to a Radiance 
2100 confocal/multiphoton system using a Plan Fluor 60×, NA 1.4, oil IR 
objective lens (both from Bio-Rad Laboratories). Cells were subjected to a 
488-nm argon laser light source with emission at 528 nm. Baseline moni-
toring was followed by addition of lacritin or the deletion fragments in 
  phenol red–free HBSS. Images were acquired at 2–3-s intervals using 
  LaserSharp2000 software (Bio-Rad Laboratories) and stored on disc for 
later analysis. Cells were depleted of STIM1 or TRPC1 by siRNA and stimu-
lated with lacritin. In other assays, cells were treated with 10 μM BHQ for 
15 min in Ca
2+/phenol red–free HBSS and stimulated with 10 nM lacritin. 
Later, 1.5 mM Ca
2+ was added. For translocation assays, HSG cells on 
Matrigel-coated coverslips with or without inhibitors were treated with 10 nM 
lacritin or positive control, 200 nM PMA, or vehicle for 15 min, washed 
with PBS, formaldehyde-ﬁ  xed, blocked with PBS containing 1% BSA and 
10% goat serum, and incubated with anti-PKCα (C-20) or anti-NFATC1 
(mAb 7A6; both from Santa Cruz Biotechnology, Inc.), followed by second-
ary Cy3-, FITC-, or Alexa Fluor 488–labeled antibodies and confocal 
  microscopic visualization (Radiance 2100; Bio-Rad Laboratories). In colo-
calization studies, we used anti-PKCα (H-7; Santa Cruz Biotechnology, 
Inc.), anti-PLCγ2 (Cell Signaling Technology), and puriﬁ  ed anti-PLD1 (from 
serum 41) provided by D. Shields (Albert Einstein College of Medicine of 
Yeshiva University, New York, NY). For NFATC1 blots, nuclei from lacritin-
treated cells without or with inhibitors were puriﬁ  ed, separated by SDS-
PAGE, blotted, and detected with anti-NFATC1. As loading control, anti-Ran 
antibody was provided by I. Macara (University of Virginia, Charlottes-
ville, VA). For measurement of IP3 generation, HSG cells were incubated SF 
in 2-[
3H]myo-inositol for 24 h, washed, and treated with 10 nM lacritin or 
C-25 or 100 μM carbachol. Processing was as previously described by 
Webb et al. (1995). Measurement of calcineurin activity used the Calci-
neurin Cellular Activity Assay kit (Calbiochem). 80–90%-conﬂ  uent  HSG 
cells in 6-well plates were treated in triplicate and collected for assay of 
calcineurin activity.
Statistical analyses
All experiments were performed at least three times. Data are presented as 
the mean ± the SEM.
Online supplemental material
Fig. S1 (A and B) display lacritin mitogenic time course and conﬂ  uency 
analyses, respectively. Fig. S2 documents lacritin-dependent generation LACRITIN MITOGENIC SIGNALING • WANG ET AL. 699
of IP3. Fig. S3 analyzes lacritin-dependent Ca
2+ inﬂ  ux in cells depleted 
of STIM1 or TRPC1. Fig. S4 quantitates the proportion of lacritin-treated 
cells in which NFAT is nuclear. Cells were treated with 10 nM lacritin for 
15 min. Nuclear localization was conﬁ  rmed by DAPI. Normal, U73122-
inhibited, and STIM1- and TRPC1-depleted cells are compared. Online 
supplemental material is available at http://www.jcb.org/cgi/content/
full/jcb.200605140/DC1.
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